Kinetic quantitative analysis reveals the suppression of Sup35NM amyloid fibril nucleation by liquid-liquid phase separation.

01 November 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Amyloid fibril formation is involved in various human diseases, such as amyotrophic lateral sclerosis and Parkinson’s disease. Many amyloidogenic proteins undergo liquid–liquid phase separation (LLPS), forming liquid-like droplets of condensed proteins. Although these droplets represent potential amyloid nucleation sites, the kinetics of amyloid nucleation in droplets is poorly understood owing to the lack of quantitative analytical methods. This study aimed to develop a measurement method for the determination of amyloid droplet nucleation rate based on image analysis. Here, the prion determinant domain of the yeast prion protein Sup35 (Sup35NM), which is known as a model protein of prion diseases, was used for demonstration. Droplets (1–20 µm in size) of Sup35NM were fixed in agarose gels, and amyloid nucleation in each droplet was counted via confocal microscopy. From the comparison of the amyloid nucleation rates in the droplets and aqueous solutions, we found a critical concentration (C*) of Sup35NM: amyloid nucleation is suppressed by LLPS above C*, whereas it is enhanced below C*. These results highlight that droplet formation can suppress amyloid nucleation, contrary to current hypotheses in which the amyloid nucleation is enhanced by droplet formation. The proposed quantitative measurement method can provide accurate assessment of the role of LLPS for amyloidosis-related proteins from pathological perspectives.

Supplementary materials

Title
Description
Actions
Title
SI
Description
Supproting data.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.